Department Metrics

• Imaging Acidosis and Immune Therapy in PDAC
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Gillies, R.,PI (MPI):Pilon-Thomas, S.
• Impact of extracellular glutathione catabolism on triple-negative breast cancer
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:DeNicola, G.
• Ecology and Evolution of Breast Carcinogenesis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Silva, A.
• Translational studies for targeted alpha-particle therapy for rare melanomas
  Award Number:
  Sponsor: US Army
  PI:Morse, D.
• Improving therapy for leptomeningeal Non-Hodgkin B cell lymphoma by targeting the metabolic tumor microenvironment
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Smalley, I.

CLINICAL TRIAL 50521
Integrated Plasma Metabolomic and Cytokine Profiling to Characterize Cancer Cachexia
Condition: Thoracic
Intervention:

• Weinfurtner RJ, Ataya D, Funaro K, Bhatt A, Abdalah M, Stringfield O, Raghunand N, Thompson Z, Lee MC, Czerniecki B, Muller AS, Soliman H, Han H. Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy. Clin Imaging. 2025 Nov.127:110618. Pubmedid: 40945432.
• Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Oct. Pubmedid: 41072416.
• Meads MB, Zhao X, Noyes DR, Sudalagunta P, Achille A, Zhang C, Renatino Canevarolo R, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil S, Yoder SJ, Grajales-Cruz AF, Blue BJ, Freeman CL, Kim J, Alsina M, Brayer J, Siqueira Silva A, Song X, Shain KH, Baz RC. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2025 Sep. Pubmedid: 40983035.
• Tauro M, Li T, Sudalagunta PR, Meads M, Canevarolo RR, Nerlakanti N, Alugubelli RR, Lawrence HR, Gunawan S, Ayaz M, Nareddy P, Yun SY, Shay G, Yang K, Tran TH, Bishop RT, Nasr MM, Lawrence NNJ, Schönbrunn E, Cleveland JL, Silva AS, Shain KH, Lynch CC. Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myeloma. Res Sq. 2025 Aug. Pubmedid: 40831505. Pmcid: PMC12363935.
• Piña Y, Law V, Sahebjam S, Tran N, Siddarajappa N, Li J, Mo Q, Phadke MS, Arrington J, Macaulay R, Mokhtari S, Evernden B, Ahmed KA, Smalley I, Yu M, Smalley KSM, Forsyth PA. Phase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses. Neurooncol. 2025 Aug. Pubmedid: 40888040.
• Persi E, Sudalagunta PR, Wolf YI, Canevarolo RR, Damaghi M, Shain KH, Silva AS, Koonin EV. Genome-level selection in tumors as a universal marker of resistance to therapy. Nat Commun. 2025 Jul.16(1):6535. Pubmedid: 40664650. Pmcid: PMC12263839.
• Andreani C, Bartolacci C, Melegari M, Sargentoni N, Luciani L, Marucci A, Galeazzi R, DeNicola GM, Kilgore J, Williams N, Berto S, Gaetani M, Pattabhi P, Osman SS, Mansour AT, Pucciarelli S, Galassi R, Scaglioni PP. Thioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers. bioRxiv. 2025 Jul. Pubmedid: 40766571. Pmcid: PMC12324224.
• Bishop RT, Li T, Sudalagunta P, Nasr M, Nyman KJ, Alugubelli RR, Meads M, Frieling J, Nerlakanti N, Tauro M, Fang B, Grant S, Koomen J, Silva AS, Shain KH, Lynch CC. Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma. Haematologica. 2025 Jun.110(6):1351-1367. Pubmedid: 39633543. Pmcid: PMC12130774.
• Sherwood AM, Yasseen BA, DeBlasi JM, Caldwell S, DeNicola GM. Distinct roles for the thioredoxin and glutathione antioxidant systems in Nrf2-Mediated lung tumor initiation and progression. Redox Biol. 2025 Jun.83:103653. Pubmedid: 40334547. Pmcid: PMC12133717.
• Renatino Canevarolo R, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst LA, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer JB, Dalton WS, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Res Sq. 2025 Apr. Pubmedid: 40321765. Pmcid: PMC12048002.
• Cuadrado A, Cazalla E, Bach A, Bathish B, Naidu SD, DeNicola GM, Dinkova-Kostova AT, Fernández-Ginés R, Grochot-Przeczek A, Hayes JD, Kensler TW, León R, Liby KT, López MG, Manda G, Shivakumar AK, Hakomäki H, Moerland JA, Motohashi H, Rojo AI, Sykiotis GP, Taguchi K, Valverde ÁM, Yamamoto M, Levonen AL. Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. Redox Biol. 2025 Apr.81:103569. Pubmedid: 40059038. Pmcid: PMC11970334.
• Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: 39652773.
• Ospina OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, Smalley I, Tsai KY, Markowitz J, Vallebuona E, Berglund AE, Eschrich SA, Yu X, Fridley BL. spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data Analysis. Cancer Res. 2025 Mar.85(5):848-858. Pubmedid: 39636739. Pmcid: PMC11873723.
• Roy J, Putt KS, Coppola D, Leon ME, Khalil FK, Centeno BA, Clark N, Stark VE, Morse DL, Low PS. Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue. Oncotarget. 2025 Mar.16:132. Pubmedid: 40042992. Pmcid: PMC11884436.
• Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma. Cancer Res. 2025 Jan.85(2):378-398. Pubmedid: 39476082. Pmcid: PMC11733535.
• Jasani N, Xu X, Posorske B, Kim Y, Wang K, Vera O, Tsai KY, DeNicola GM, Karreth FA. PHGDH Induction by MAPK Is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability. Cancer Res. 2025 Jan.85(2):314-328. Pubmedid: 39495254. Pmcid: PMC11735329.
• Lazure F, Drapela S, Liu X, Lockhart JH, Kashfi H, Sarigul N, Ilter D, Flores ER, Wang X, Smalley I, Jaeger A, Yu X, Gomes AP. Aging directs the differential evolution of KRAS-driven lung adenocarcinoma. bioRxiv. 2025 Jan. Pubmedid: 39896625. Pmcid: PMC11785146.
• Messina MS, Torrente L, Pezacki AT, Humpel HI, Li EL, Miller SG, Verdejo-Torres O, Padilla-Benavides T, Brady DC, Killilea DW, Killilea AN, Ralle M, Ward NP, Ohata J, DeNicola GM, Chang CJ. A histochemical approach to activity-based copper sensing reveals cuproplasia-dependent vulnerabilities in cancer. Proc Natl Acad Sci U S A. 2025 Jan.122(3). Pubmedid: 39813247. Pmcid: PMC11761388.
• Greenwood HE, Barber AR, Edwards RS, Tyrrell WE, George ME, Dos Santos SN, Baark F, Tanc M, Khalil E, Falzone A, Ward NP, DeBlasi JM, Torrente L, Soni PN, Pearce DR, Firth G, Smith LM, Vilhelmsson Timmermand O, Huebner A, Swanton C, Hynds RE, DeNicola GM, Witney TH. Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography. Nat Commun. 2024 Dec.15(1):10484. Pubmedid: 39690148. Pmcid: PMC11652680.
• Li L, Hu X, Nkwocha J, Kmieciak M, Meads MB, Shain KH, Alugubelli RR, Silva AS, Mann H, Sudalagunta PR, Canevarolo RR, Zhou L, Grant S. Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo. Brit J Haematol. 2024 Dec.205(6):2338-2348. Pubmedid: 39379134. Pmcid: PMC11650795.
• Jiang Y, El Khoury E, Pezacki AT, Qian N, Oi M, Torrente L, Miller SG, Ralle M, DeNicola GM, Min W, Chang CJ. An Activity-Based Sensing Approach to Multiplex Mapping of Labile Copper Pools by Stimulated Raman Scattering. J Am Chem Soc. 2024 Dec.146(49):33324-33337. Pubmedid: 39586074.
• Huynh AS, Cohen AS, Doligalski M, Casagni TJ, Moberg VE, Huang X, Morse J, Abrahams D, Lloyd MC, Centeno BA, Baldwin MK, McLaughlin ML, Vagner J, Morse DL. Intraoperative Guidance of Pancreatic Cancer Resection Using a Toll-like Receptor 2-Targeted Fluorescence Molecular Imaging Agent. Cancer Res Commun. 2024 Nov.4(11):2877-2887. Pubmedid: 39320054. Pmcid: PMC11536076.
• Gantner BN, Palma FR, Pandkar MR, Sakiyama MJ, Arango D, DeNicola GM, Gomes AP, Bonini MG. Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes. Trends Cancer. 2024 Nov.10(11):992-1008. Pubmedid: 39277448.